The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

Johnson & Johnson (NYSE:JNJ) has entered a clinical supply agreement with GI Innovation to test a bispecific immunotherapy ...

The 2026 PSMA & Beyond conference featured a targeting the cell surface session and presentation by Dr. Tanya Dorff discussing antibody drug conjugates and BiTEs and their role in prostate cancer. Dr.

But does it cost too much?

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

The state of prostate cancer in the U.S. is not exactly great. Just take a look at the “Prostate cancer statistics, 2025” report from the American Cancer Society, published at the beginning of ...